Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Serina Therapeutics (SER) Other Non Operating Income (2018 - 2025)

Serina Therapeutics (SER) has disclosed Other Non Operating Income for 8 consecutive years, with -$100000.0 as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 332.56% to -$100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50000.0 through Dec 2025, down 78.07% year-over-year, with the annual reading at $51000.0 for FY2025, 77.63% down from the prior year.
  • Other Non Operating Income hit -$100000.0 in Q4 2025 for Serina Therapeutics, down from $35000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $437000.0 in Q1 2021 to a low of -$100000.0 in Q4 2025.
  • Historically, Other Non Operating Income has averaged $47000.0 across 5 years, with a median of $19500.0 in 2021.
  • Biggest five-year swings in Other Non Operating Income: surged 8640.0% in 2021 and later tumbled 332.56% in 2025.
  • Year by year, Other Non Operating Income stood at $3000.0 in 2021, then skyrocketed by 33.33% to $4000.0 in 2022, then soared by 2125.0% to $89000.0 in 2023, then plummeted by 51.69% to $43000.0 in 2024, then crashed by 332.56% to -$100000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for SER at -$100000.0 in Q4 2025, $35000.0 in Q3 2025, and $68000.0 in Q2 2025.